Sign inStart free

Health Care · Biological Products, (No Diagnostic Substances)

IMVT Immunovant, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 176401392 filings
Russell 2000
Follow IMVT for alertsAsk AI about IMVT

IMVT at a glance

Immunovant, Inc. (IMVT, SEC CIK 1764013) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 3, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Immunovant, Inc. (IMVT) shares worth $1.9 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Venker Eric on October 2, 2026 of 3,506 shares at $34.11 per share.
  • In the last 90 days, IMVT insiders reported 0 open-market purchases ($0) and 7 open-market sales ($856K) on Form 4, a net sale of $856K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 7 sells
Net −$856K
13F holders
29 funds
$1.9B · +4 vs prior quarter
Latest 8-K
Sep 3, 2026
Item 5.07

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Management Discussion & Analysis

  • Cash and equivalents $797.8M as of June 30, 2026, expected to fund operations through potential IMVT-1402 GD launch
  • Potential late-stage development expansion under evaluation following positive D2T RA Period 1 results
  • Updated cash runway guidance expected after D2T RA and CLE Period 2 results later this year
  • Continued net losses anticipated, with current funds insufficient for all planned development and commercialization activities

Risk Factors

  • Interim or topline data risk: audit, verification, and additional patient data may materially change reported clinical results
  • Clinical-trial execution risk: enrollment, site activation, CRO performance, and manufacturing constraints may delay studies
  • Regulatory compliance risk: FDA or other authorities may impose clinical holds for GCP, safety, protocol, or data-integrity deficiencies
  • Commercial risk: delayed trials could let competitors launch earlier and shorten exclusivity periods
  • Data-integrity risk: pre-acquisition research deficiencies at licensing partners could increase development costs and delay commercialization

AI summary of the IMVT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Sep 3, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • 198,373,370 shares represented, approximately 96% of eligible voting shares, indicating strong shareholder participation
  • Bauer, Hughes, and Susman re-elected to the Board through the 2027 annual meeting
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal first-quarter results ended June 30, 2026, released August 6, 2026
  • Full financial details contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • IMVT-1402 timelines remain on track across six autoimmune indications, with GD and MG topline data expected in 2027
  • Cash $797.8M supports potential IMVT-1402 launch in GD, but quarterly cash declined from $902.1M at March 31, 2026
Filed May 20, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal fourth-quarter and fiscal-year results covered period ended March 31, 2026
  • Press release issued May 20, 2026 and furnished as Exhibit 99.1

AI summaries of IMVT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IMVT

Don't miss the next IMVT filing

  • Alerts as it files. A push when IMVT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IMVT, by share count.
  • Ask anything. An AI agent that reads every IMVT filing and answers with sources.
Follow IMVT for alertsAsk AI about IMVT
Compare plans →

IMVT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Venker EricSellOct 2, 2026$34.11
Venker EricMOct 1, 2026$14.46
Venker EricDOct 1, 2026$33.65
Venker EricMOct 1, 2026-
Van Tuyl ChristopherSellSep 23, 2026$36.36
Pande AtulSellAug 28, 2026$43.27
Pande AtulMAug 28, 2026-
Pande AtulMAug 28, 2026$8.43
Insider trades across all companies →Which insider buys matter →

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Net Income-$259.3M-$413.8M-$505.6M
Balance Sheet
Total Assets$666.4M$776.2M$957.0M
Equity$617.8M$707.4M$852.6M
ROE-42.0%-58.5%-59.3%
Per Share
EPS$-1.88$-2.73$-2.77
Cash Flow
Operating CF-$214.2M-$375.9M-$407.3M
CapEx$360K$759K$8K

Source: XBRL data in Immunovant, Inc. (IMVT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate IMVT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IMVT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202629$1.89B
Q1 202625$1.09B
Q4 202520$1.11B
Q3 202520$595.0M
Q2 202523$660.1M
Q1 202521$600.2M
Q4 202419$703.2M
Q3 202416$294.4M
Position changes: Q1 2026 → Q2 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 173 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IMVT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

10-K annual reports

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Oct 5, 2026--
4Sep 25, 2026--
8-KSep 3, 2026Analysis-
4Aug 28, 2026--
4Aug 21, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 24, 2026--
4Jul 24, 2026--
4Jul 24, 2026--
4Jul 10, 2026--
4Jul 10, 2026--
4Jul 10, 2026--
4Jul 6, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 22, 2026--
4Jun 16, 2026--
4May 29, 2026-
4May 22, 2026-
8-KMay 20, 2026Analysis
10-KMay 20, 2026-

Related Health Care companies

All Health Care →

IMVT SEC filings: frequently asked questions

Are IMVT insiders buying or selling?

In the last 90 days, Immunovant, Inc. (IMVT) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $856,180 by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold IMVT stock?

As of June 30, 2026, the largest Immunovant, Inc. (IMVT) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($623.7 million), BlackRock ($276.7 million), State Street Corp ($177.9 million), Morgan Stanley ($174.7 million), Vanguard Portfolio Management LLC ($150.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did IMVT report in its latest 8-K?

Immunovant, Inc. (IMVT) filed an 8-K on September 3, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 198,373,370 shares represented, approximately 96% of eligible voting shares, indicating strong shareholder participation.

What are the latest IMVT SEC filings?

Immunovant, Inc. (IMVT) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 3, 2026 and a Form 4 insider filing on October 5, 2026.

What is IMVT's SEC CIK number?

Immunovant, Inc. (IMVT)'s SEC Central Index Key (CIK) is 1764013. EDGAR lists every IMVT filing under that number.

Ask anything about IMVT

The research agent reads IMVT's filings, financials, insider trades and 13F holders, then answers with sources.

Start free